PR Archives - Upperton Pharma Solutions

DDL 2025 – The Next Chapter in Inhalation

December 17, 2025 by Rob Halliwell

• The pressure of speed to clinic is continuing to increase. Biotechs are under more pressure, and therefore the CDMOs supporting them must evolve too

Business Development Spotlight with Christopher Bjerkan Wade

December 15, 2025December 11, 2025 by Rob Halliwell

Discover more about our team. In this Spotlight, meet our Senior Business Development Director, Christopher Bjerkan Wade.

The Evolution of Biotech and CDMO Partnerships

December 10, 2025December 10, 2025 by Rob Halliwell

• The pressure of speed to clinic is continuing to increase. Biotechs are under more pressure, and therefore the CDMOs supporting them must evolve too

Developments in OSD Manufacturing: What Biotechs Need to Know

November 24, 2025November 20, 2025 by Libby Turford

What do biotechs need to know about oral solid dose manufacturing? Learn about how partnering with a CDMO can provide a competitive edge

What’s Next in Pharmaceutical R&D? A Conversation with Upperton’s Director of Pharmaceutical Sciences

November 18, 2025November 17, 2025 by Libby Turford

We speak to Upperton’s Director of Pharmaceutical Sciences, Laura Mason, about the upcoming trends she sees emerging in the R&D lab.

Does a One-Site CDMO Make a Difference in Drug Development?

November 26, 2025November 6, 2025 by Libby Turford

A one-site CDMO is where GMP, R&D and manufacturing all operate on one site, making the movement of projects streamlined.

Tech Transfer in Late-Stage Oral Solid Dose Projects: Lessons Learnt and Best Practices from a CDMO Perspective

November 27, 2025November 5, 2025 by Libby Turford

Tech transfer in oral solid dose (OSD) manufacturing is one of the most critical, and often underestimated, phases in the drug development lifecycle. For CDMOs, it’s a moment where scientific precision meets operational discipline.